- Home
- BTTC vs BIVI Comparison
BTTC vs BIVI Comparison
Compare BTTC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTTC | BIVI |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BTTC | BIVI |
|---|---|---|
| Price | $0.93 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 106.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $0.88 |
| 52 Week High | $11.22 | $9.09 |
Technical Indicators
Market Signals| Indicator | BTTC | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 57.50 |
| Support Level | N/A | $1.17 |
| Resistance Level | $1.41 | $1.71 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 0.06 | 68.75 |
Price Performance
Historical ComparisonAbout BTTC Black Titan Corporation Ordinary Shares
Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.